Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | BCHE | P06276 | 5/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915350 | 1.00 | ACHE (0.47) | ACHEBCHECHRM3BACE1SCN4A | |
| SCHEMBL7225784 | 0.86 | CYP2D6 (0.53) | ACHEBCHESCN4AMAOB | |
| SCHEMBL7225528 | 0.86 | CYP2D6 (0.53) | ACHEBCHESCN4AMAOB | |
| SCHEMBL7225251 | 0.86 | CYP2D6 (0.53) | ACHEBCHESCN4AMAOB | |
| SCHEMBL7225790 | 0.86 | CYP2D6 (0.53) | ACHEBCHESCN4AMAOB | |
| SCHEMBL7225533 | 0.86 | CYP2D6 (0.53) | ACHEBCHESCN4AMAOB | |
| SCHEMBL3227659 | 0.84 | BCHE (0.57) | BCHEMAOB | |
| SCHEMBL10713365 | 0.82 | BCHE (0.46) | ACHEBCHESCN4AMAOB | |
| SCHEMBL914658 | 0.81 | BCHE (0.62) | ACHEBCHECHRM3MEN1KMT2A | |
| SCHEMBL15710626 | 0.79 | ACHE (0.48) | ACHEBCHEBACE1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354431-B2 | Aryl carboxylic acid cyclohexyl amide derivatives | NOVARTIS AG (CH) | 2013-01-15 | — | — | US | disclosed |
| US-8354431-B2 | Aryl carboxylic acid cyclohexyl amide derivatives | NOVARTIS AG (CH) | 2013-01-15 | — | — | US | disclosed |
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-01-21 | — | — | US | disclosed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | ACHE 4338/4885BCHE 2386/4885CHRM3 580/4885 |
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | ACHE 4358/4885BCHE 2327/4885CHRM3 554/4885 |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | CYP2D6, CYP2B6, CYP2C9 | ACHE 3548/4885BCHE 1522/4885CHRM3 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.